

Attorney Docket No.PC10325AAAKM

IN THE UNITED STATES PATENT AND TRADEMARK OFFI

IN RE APPLICATION OF: MICHAEL E. WYLLIE

APPLICATION NO.: NOT YET ASSIGNED

Examiner: NOT YET **ASSIGNED**

FILING DATE: HEREWITH

Group Art Unit: NOT YET

ASSIGNED

TITLE: PHARMACEUTICAL COMBINATIONS

Hon. Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 are enclosed. C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application references. (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: February 5, 500/

Respectfully submitted,

Arlene K. Musser

Attorney for Applicant(s)

Reg. No. 37,895

Pfizer Inc. Patent Department, MS 4159 Eastern Point Road Groton, Connecticut 06340 (860) 715-0871

INFORMATION DISCLOSURE STATEMENT, 9/99, (1/1)

